复发性生殖器疱疹阿昔洛韦抑制疗法撤药后疗效的系统评价

发布时间：2018-10-12 15:54

【摘要】：目的对抑制疗法治疗复发性生殖器疱疹患者在撤药后的疗效进行系统评价。方法检索Pubmed,Embase,Cochrane图书馆和中国生物医学文献数据库,纳入抑制疗法与安慰剂和/或间歇疗法作对照治疗频繁复发的生殖器疱疹的随机试验。对纳入文献进行方法学质量评估,采用RevMan5.2对撤药后的风险比及复发频率进行Meta分析。结果纳入的3个随机对照试验均为阿昔洛韦与安慰剂对照,共纳入了1 349例患者,随访对象仅有273例。研究的方法学质量均不高,亚组分析评估风险比未发现两组差异存在显著的统计学意义,撤药后的平均复发频率差异也无统计学意义(P=0.30)。结论与安慰剂相比,阿昔洛韦抑制疗法不能显著减少生殖器疱疹频繁复发者在撤药后的复发频率,对疾病的自然病程可能没有显著影响。
[Abstract]:Objective to evaluate the efficacy of inhibition therapy in the treatment of recurrent genital herpes. Methods the Pubmed,Embase,Cochrane library and the Chinese Biomedical Literature Database were searched and randomized trials were conducted to compare inhibition therapy with placebo and / or intermittent therapy in the treatment of recurrent genital herpes. The methodological quality of the literature was evaluated and the risk ratio and recurrence frequency after withdrawal were analyzed by RevMan5.2 by Meta. Results all of the 3 randomized controlled trials were controlled by acyclovir and placebo. A total of 1 349 patients were enrolled and only 273 patients were followed up. The methodological quality of the study was not high. There was no significant difference in risk assessment between the two groups by subgroup analysis, and there was no significant difference in the average recurrence frequency after withdrawal (P0. 30). Conclusion compared with placebo, acyclovir inhibition therapy can not significantly reduce the recurrence frequency of patients with recurrent genital herpes after withdrawal, and may not have significant effect on the natural course of the disease.
【作者单位】：江苏大学附属医院皮肤科;
【基金】：江苏省镇江市科技局项目(2101)
【分类号】：R752.1

【共引文献】